What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus
Publication in refereed journal

Times Cited
Altmetrics Information

Other information
AbstractThere is increasing evidence that the pathophysiology of type 2 diabetes mellitus (T2DM) in Asian patients differs from that in Western patients, with early phase insulin deficiencies, increased postprandial glucose excursions, and increased sensitivity to insulin. Asian patients may also experience higher rates of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as nausea and vomiting, compared with their Western counterparts. These factors should be taken into consideration when selecting therapy for basal insulin treatment intensification in Asian patients. However, the majority of studies to establish various agents for treatment intensification in T2DM have been conducted in predominantly Western populations, and the levels of evidence available in Chinese or Asian patients are limited. This review discusses the different mechanisms of action of short-acting, prandial, and long-acting GLP-1RAs in addressing hyperglycemia, and describes the rationale and available clinical data for basal insulin in combination with the short-acting prandial GLP-1RA lixisenatide, with a focus on treatment of Asian patients with T2DM.
All Author(s) ListChan WB, Luk A, Chow WS, Yeung VTF
Journal nameJournal of Diabetes
Volume Number9
Issue Number6
Pages562 - 574
LanguagesEnglish-United Kingdom
Keywordsinsulin,lixisenatide,type 2 diabetes mellitus
Web of Science Subject CategoriesEndocrinology & Metabolism;Endocrinology & Metabolism

Last updated on 2021-14-04 at 00:16